Highest-materiality recent filing
Kyverna appoints Greg Martini as CFO; Marc Grasso transitions to strategic advisor
Greg Martini named CFO effective May 18, 2026; previously CFO of Ironwood Pharmaceuticals.
Kyverna reports Q1 net loss $39.7M; initiates rolling BLA for miv-cel in SPS
Cash, cash equivalents and marketable securities of $236.4M as of March 31, 2026; cash runway expected into 2028.
Kyverna's miv-cel meets all endpoints in KYSA-8 SPS trial; median T25FW improvement 46% (p=0.0003)
Single-dose miv-cel achieved statistically significant improvements across all primary and secondary endpoints at Week 16.
Kyverna reports positive miv-cel Phase 2 data in gMG and registrational SPS trial
KYSA-6 Phase 2/3 trial of miv-cel in generalized myasthenia gravis: positive longer-term follow-up from Phase 2 portion.
Kyverna Phase 2 miv-cel data shows 100% response rate at 24 weeks in gMG; durable to 52 weeks
100% of 7 patients achieved ≥3-point reduction in MG-ADL and QMG (co-primary endpoints) at 24 weeks; mean reductions -8.5 and -11.3 points.
Kyverna reports Q4/FY2025 results; cash $279M, SPS BLA on track for 1H 2026
Net loss $37.8M Q4, $161.3M FY2025; R&D $30.0M Q4, G&A $9.3M Q4.
Kyverna appoints Andrew Miller and Sravan Emany to Board; Spiegelman resigns
Andrew Miller (Karuna founder) appointed Class III director; granted option valued at $262k and RSUs valued at $87.5k.
Kyverna appoints Mayo Pujols as CTO; Karen Walker retires effective Feb 9, 2026
Mayo Pujols named CTO effective Feb 9, bringing 30+ years in CAR T and cell therapy manufacturing.
Kyverna plans BLA for miv-cel in SPS in 1H 2026; Christi Shaw appointed Executive Chair
BLA submission for miv-cel in stiff person syndrome expected in 1H 2026 following positive registrational data.
Kyverna prices $100M public offering of 13.3M shares at $7.50 per share
Offering of 13,333,333 shares of common stock at $7.50/share; gross proceeds ~$100M.
Primary endpoint met: 46% median improvement in timed 25-foot walk at Week 16 (p=0.0002).
Kyverna reports positive topline data from Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome
Positive topline data from registrational Phase 2 trial of miv-cel (KYV-101) in stiff person syndrome (SPS).
Kyverna reported Q3 2025 net loss of $36.8M ($0.85 per share), R&D expenses $30.5M, G&A $8.3M; cash $171.1M as of Sep 30, 2025.
Kyverna secures up to $150M debt facility from Oxford Finance; SPS data readout accelerated
Non-dilutive term loan facility of up to $150M; initial draw of $25M on Nov 3, 2025.
Kyverna reports positive Phase 2 interim data for KYV-101 in gMG; 100% response rate
100% (6/6) of patients achieved clinically meaningful reductions in MG-ADL and QMG at 24 weeks.
Kyverna reports positive interim Phase 2 data for KYV-101 in generalized myasthenia gravis
Positive interim data from Phase 2 portion of KYSA-6 trial of KYV-101 announced on October 29, 2025.
Kyverna Q2 net loss $42.1M, cash $211.7M; advances KYV-101 in SPS and MG
Net loss $42.1M ($0.97/share) vs $28.8M in Q2 2024; R&D expenses rose to $35.8M from $27.3M.
Kyverna completes SPS Phase 2 enrollment; BLA filing now 1H 2026; Q1 net loss $44.6M
Enrollment completed in KYSA-8 pivotal Phase 2 trial of KYV-101 in stiff person syndrome; topline data 1H 2026.
Kyverna reports 2024 net loss $127.5M; cash runway into 2027; SPS trial 70% enrolled
Net loss of $127.5M ($3.33 loss per share) for full year 2024 vs $60.4M loss in 2023.
Kyverna Therapeutics enters into $50M at-the-market equity offering facility with Jefferies
Agreement with Jefferies LLC allows sale of up to $50M of common stock from time to time.
Kyverna outlines 2025 priorities; pivotal SPS trial 40% enrolled, BLA filing targeted for 2026
40% enrolled in pivotal Phase 2 KYV-101 trial for stiff person syndrome; BLA filing targeted for 2026.
Kyverna CMO James Chung resigns; receives $220K severance and COBRA
CMO James Chung's employment terminated effective November 22, 2024.
Kyverna Q3 net loss $34.3M; CMO James Chung resigns effective Nov 22
Net loss of $34.3M ($0.80 per share) vs. $15.5M loss in prior-year quarter.
Kyverna appoints Warner Biddle CEO, Christi Shaw to board; Maag resigns
Warner Biddle appointed CEO and Class III director, effective Sept 16; previously SVP Global Head of Commercial at Kite Pharma.
Kyverna Q2 net loss $28.8M; cash $346.2M; RMAT designations for KYV-101
Q2 net loss $28.8M ($0.67 per share) vs $13.1M loss year ago.
Kyverna receives FDA RMAT designation for KYV-101 in refractory stiff-person syndrome
FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for KYV-101, an autologous CD19 CAR T-cell therapy.
Kyverna presents data update on KYV-101 CAR T therapy at EULAR symposium
CEO Peter Maag introduced symposium; external speakers presented long-term clinical experience with anti-CD19 CAR T in autoimmune diseases.
Kyverna reports FY 2023 net loss of $60.4M; IPO raised $366.9M in Feb 2024
Net loss $60.4M ($89.61/share) vs. $28.9M ($63.43/share) in FY 2022; cash burn $52.4M in operating activities.
Kyverna Therapeutics completes IPO of 16.7M shares at $22.00, gross proceeds $366.9M
Gross proceeds $366.9M from IPO including full exercise of underwriter option to purchase 2.175M additional shares.
On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026 (the “Effective Date”).
As previously disclosed, James Chung, M.D., Ph.D., Chief Medical Officer of Kyverna Therapeutics, Inc. (the “Company”), resigned from the Company, to be effective as of November 22, 2024.
On November 8, 2024, James Chung, M.D., Ph.D., Chief Medical Officer of the Company, resigned from the Company, to be effective as of November 22, 2024.
On October 20, 2024, the board of directors (the "Board") of Kyverna Therapeutics, Inc. (the "Company") appointed Mert Aktar as a Class III director of the Company, effective October 20, 2024.
appointed Warner Biddle as the Company’s Chief Executive Officer and as a Class III director of the Company, in each case effective September 16, 2024
Max materiality 0.90 · Median 0.68 · Most common event other_material